Lyra Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). The Company is developing therapies for CRS, a prevalent inflammatory disease of the paranasal sinuses that leads to debilitating symptoms and significant morbidities. LYR-210, the Company’s lead product, is a bioabsorbable nasal implant designed to be administered in a simple, in-office procedure and is intended to deliver six months of continuous anti-inflammatory drug therapy to the sinonasal passages for the treatment of CRS with a single administration. LYR-210, being evaluated in the ENLIGHTEN Phase III clinical program, is intended for patients with and without nasal polyps. The drug embedded within LYR-210 is mometasone furoate (MF).
Em Crescimento
A empresa está em fase de crescimento, com a receita anual mais recente totalizando US$ 1.53M.
Alto Crescimento de Lucro
O lucro líquido da empresa lidera o setor, com o lucro anual mais recente totalizando US$ 1.53M.
Sobreavaliada
O PE mais recente da empresa é -0.02, em uma faixa percentil alta de 3 anos.
Venda Institucional
As participações institucionais mais recentes são de 367.19K ações, uma redução de 65.70% em relação ao trimestre anterior.
Mantido por PRFDX
O Super Investidor PRFDX possui 110.00 ações desta empresa.